The ACOSOG ( American College of Surgeons Oncology Group ) Z@ ( Alliance ) study , a randomized , placebo-controlled trial , demonstrated that @ year of adjuvant imatinib prolonged recurrence-free survival ( RFS ) after resection of primary GI stromal tumor ( GIST ) .